TSX : HLS.TO

HLS Therapeutics Inc.

$4.19 CAD

-$0.02 (-0.48%)

Volume
1.16K
Average Volume
35.17K
Market Capitalization
$131.04M
P/E Ratio
-9.34
Dividend Yield
0.00%
Price Target
Year High
$5.77
Year Low
$0.00
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$1.00
Company Overview

TSX

Craig Stuart Millian

Drug Manufacturers - Specialty & Generic

Healthcare

HLS.TO

85

CA

CAD

https://www.hlstherapeutics.com

647-495-9000

40390B109

N/A

Liquidity Metrics

0.75

1.00

0.75

0.43

0.00

Sales & Valuation

$56.47M

1.69

1.60

5.12

0.59

Profitability

-$0.4

-$12.65M

-18.42%

-19.19%

-16.54%

-7.82%

P/E Metrics

-9.34

-0.15

-0.15

Analyst Price Target & Rating

Sell

2/5

1 Analysts

%

Financial Health Scores

-1.11

5/9

$126.09K

$131.18M

$72.57M

-$4.19M

Key Metrics (TTM)

No key metrics data available.

Company Executives
Name Title
John Hanna Chief Financial Officer & Non-Independent Director
Brian T. Walsh Chief Commercial Officer
David Spence Vice President & Corporate Controller
Craig Stuart Millian Chief Executive Officer & Director
Jason A. Gross Vice President of Scientific Affairs
Dave Mason Investor Relations Officer
Ryan C. Lennox Senior Vice President of Legal, HR & Compliance and Corporate Secretary
Poll Results

No votes yet today — be the first to share your view!

About HLS Therapeutics Inc. (TSX:HLS.TO) Stock

HLS Therapeutics Inc. operates as a specialized pharmaceutical firm, concentrating on the acquisition and commercialization of medicinal products, primarily within the niche central nervous system (CNS) and cardiovascular (CV) sectors. Its reach extends across Canada, the United States, and international markets. The company's core product lineup includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsule formulation; and PERSERIS, an injectable risperidone product for treating schizophrenia. Additionally, HLS offers MyCare psychiatry laboratory assays and MyCare Insite tests for point-of-care therapeutic drug-level monitoring. Furthermore, the company possesses U.S. marketing privileges for Absorica, a commercial-stage dermatolo ... gy solution, and Canadian rights for Trinomia, a cardiovascular therapeutic. It also manages a portfolio of royalty interests from four distinct healthcare products. Founded in 2018, HLS Therapeutics Inc. is based in Etobicoke, Canada.

Frequently Asked Questions

What is the current HLS Therapeutics Inc. (HLS.TO) stock price?

HLS Therapeutics Inc.(TSX:HLS.TO) stock price is $4.19 in the last trading session. During the trading session, HLS.TO stock reached the peak price of $5.765 while $0.001 was the lowest point it dropped to. The percentage change in HLS.TO stock occurred in the recent session was --0.48% while the dollar amount for the price change in HLS.TO stock was -$0.02.

HLS.TO's industry and sector of operation?

The TSX listed HLS.TO is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.

Who are the executives of HLS.TO?

John Hanna | Chief Financial Officer & Non-Independent Director
Brian T. Walsh | Chief Commercial Officer
David Spence | Vice President & Corporate Controller
Craig Stuart Millian | Chief Executive Officer & Director
Jason A. Gross | Vice President of Scientific Affairs

How many employees does HLS.TO have?

Number of HLS.TO employees currently stands at 85. HLS.TO operates from 10 Carlson Court, Etobicoke, ON M9W 6L2, CA.

Link for HLS.TO official website?

Official Website of HLS.TO is: https://www.hlstherapeutics.com

How do I contact HLS.TO?

HLS.TO could be contacted at phone #647-495-9000 and can also be accessed through its website. HLS.TO operates from 10 Carlson Court, Etobicoke, ON M9W 6L2, CA.

How many shares of HLS.TO are traded daily?

The average number of HLS.TO shares traded daily for last 3 months was 35.17K.

What is the market cap of HLS.TO currently?

The market value of HLS.TO currently stands at $131.04M with its latest stock price at $4.19